Practical consideration of genotype imputation: Sample size, window size, reference choice, and untyped rate

Statistics and its Interface

Volumn 4, Issue 3, 2011, Pages 339-352

  Zhang, Boshao ^a   Zhi, Degui ^a   Zhang, Kui ^a   Gao, Guimin ^b   Limdi, Nita A ^a,c   Liu, Nianjun ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c The University of Alabama at Birmingham   (United States)

Author keywords

Admixed population; Genetic study; Genotype imputation; Reference; Untyped rate; Window size

Indexed keywords

EID: 84864383723     PISSN: 19387989     EISSN: 19387997     Source Type: Journal    
DOI: 10.4310/sii.2011.v4.n3.a8     Document Type: Article

References (62)

1. Alexander, D. H., Novembre, J. and Lange, K. 2009. Fast modelbased estimation of ancestry in unrelated individuals. Genome Res. 19(9):1655-1664.
2. Altshuler, D., Gibbs, R., Peltonen, L., Dermitzakis, E., Schaffner, S., Yu, F., Bonnen, P., de Bakker, P., Deloukas, P., Gabriel, S., et al. 2010. Integrating common and rare genetic variation in diverse human populations. Nature 467(7311):52-58.
3. Anderson, C., Pettersson, F., Barrett, J., Zhuang, J. and Ragoussis, J. 2008a. Evaluating the effects of imputation on the power, coverage, and cost efficiency of genome-wide SNP platforms. Am. J. Hum. Genet. 83:112-119.
4. Anderson, C., Pettersson, F., Barrett, J., Zhuang, J. and Ragoussis, J. 2008b. Evaluating the effects of imputation on the power, coverage, and cost efficiency of genome-wide SNP platforms. Am. J. Hum. Genet. 83:112-119.
5. Aquilante, C., Langaee, T., Lopez, L., Yarandi, H., Tromberg, J., Mohuczy, D., Gaston, K., Waddell, C., Chirico, M. and Johnson, J. 2006. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4):291-302.
6. Aulchenko, Y., Struchalin, M. and van Duijn, C. 2010. ProbABEL package for genome-wide association analysis of imputed data. BMC Bioinformatics 11:134.
7. Borgiani, P., Ciccacci, C., Forte, V., Romano, S., Federici, G. and Novelli, G. 2007. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8(11):1545-1550.
8. Browning, S. R. 2008. Missing data imputation and haplotype phase inference for genome-wide association studies. Hum. Genet. 124:439-450.
9. Browning, S. R. and Browning, B. L. 2007. Rapid and accurate haplotype phasing and missing-data inference for whole-genome association studies by use of localized haplotype clustering. Am. J. Hum. Genet. 81(5):1084-1097.
10. Budnitz, D., Shehab, N., Kegler, S. and Richards, C. 2007. Medication use leading to emergency department visits for adverse drug events in older adults. Ann. Intern. Med. 147(11):755-765.
11. Caldwell, M., Berg, R., Zhang, K., Glurich, I., Schmelzer, J., Yale, S., Vidaillet, H. and Burmester, J. 2007. Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5(1):8-16.
12. Carlquist, J., Horne, B., Mower, C., Park, J., Huntinghouse, J., McKinney, J., Muhlestein, J. and Anderson, J. 2010. An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction. J. Thromb. Thrombolysis 30(3):358-364.
13. Cho, H., Sohn, K., Park, H., Lee, K., Choi, B., Kim, S., Kim, J., On, Y., Chun, M., Kim, H., et al. 2007. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8(4):329-337.
14. Consortium TWTC-C. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661-678.
15. Crawford, D., Carlson, C., Rieder, M., Carrington, D., Yi, Q., Smith, J., Eberle, M., Kruglyak, L. and Nickerson, D. 2004. Haplotype diversity across 100 candidate genes for inflammation, lipid metabolism, and blood pressure regulation in two populations. Am. J. Hum. Genet. 74(4):610-622.
16. Crawford, D., Ritchie, M. and Rieder, M. 2007. Identifying the genotype behind the phenotype: a role model found in VKORC1 and its association with warfarin dosing. Pharmacogenomics 8(5):487-496.
17. D'Andrea, G., D'Ambrosio, R., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E. and Margaglione, M. 2005. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105(2):645-649.
18. de Bakker, P. I., Burtt, N. P., Graham, R. R., Guiducci, C., Yelensky, R., Drake, J. A., Bersaglieri, T., Penney, K. L., Butler, J., Young, S., et al. 2006. Transferability of tag SNPs in genetic association studies in multiple populations. Nat. Genet. 38(11):1298-1303.
19. Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. and Idle, J. 1995. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5(6):389-392.
20. Gabriel, S. B., Schaffner, S. F., Nguyen, H., Moore, J. M., Roy, J., Blumenstiel, B., Higgins, J., DeFelice, M., Lochner, A., Faggart, M., et al. 2002. The structure of haplotype blocks in the human genome. Science 296(5576):2225-2229.
21. Gage, B., Eby, C., Johnson, J., Deych, E., Rieder, M., Ridker, P., Milligan, P., Grice, G., Lenzini, P., Rettie, A., et al. 2008. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3):326-331.
22. Hao, K., Chudin, E., McElwee, J. and Schadt, E. E. 2009. Accuracy of genome-wide imputation of untyped markers and impacts on statistical power for association studies. BMC Genet. 10:27.
23. Huang, L., Li, Y., Singleton, A. B., Hardy, J. A., Abecasis, Ga., Rosenberg, N. A. and Scheet, P. 2009a. Genotype-imputation accuracy across worldwide human populations.Am. J. Hum. Genet. 84:235-250.
24. Huang, L., Li, Y., Singleton, A. B., Hardy, J. A., Abecasis, Ga., Rosenberg, N. A. and Scheet, P. 2009b. Genotype-imputation accuracy across worldwide human populations.Am. J. Hum. Genet. 84:235-250.
25. Huang, L., Wang, C. and Rosenberg, N. A. 2009c. The relationship between imputation error and statistical power in genetic association studies in diverse populations. Am. J. Hum. Genet. 85(5):692-698.
26. Klein, T., Altman, R., Eriksson, N., Gage, B., Kimmel, S., Lee, M., Limdi, N., Page, D., Roden, D., Wagner, M., et al. 2009. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8):753-764.
27. Kuffner, T., Whitworth, W., Jairam, M. and McNicholl, J. 2003. HLA class II and TNF genes in African Americans from the Southeastern United States: regional differences in allele frequencies. Hum. Immunol. 64(6):639-647.
28. Li, Y., Willer, C., Ding, J., Scheet, P. and Abecasis, G. 2010. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genetic Epidemiology 34(8):816-834.
29. Li, Y., Willer, C., Sanna, S. and Abecasis, G. 2009. Genotype imputation. Annual Review Genomics and Human Genetics 10:387-406.
30. Limdi, N., Arnett, D., Goldstein, J., Beasley, T., McGwin, G., Adler, B. and Acton, R. 2008a. Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9(5):511-526.
31. Limdi, N., Beasley, T., Crowley, M., Goldstein, J., Rieder, M., Flockhart, D., Arnett, D., Acton, R. and Liu, N. 2008b. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9(10):1445-1458.
32. Limdi, N., Limdi, M., Cavallari, L., Anderson, A., Crowley, M., Baird, M., Allon, M. and Beasley, T. 2010a. Warfarin dosing in patients with impaired Kidney function. Am. J. Kidney Dis.
33. Limdi, N. and Veenstra, D. 2008. Warfarin pharmacogenetics. Pharmacotherapy 28(9):1084-1097.
34. Limdi, N., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D., Lee, M., Chen, C., Motsinger-Reif, A., Sagreiya, H., Liu, N., et al. 2010b. Warfarin pharmacogenetics: A single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115(18):3827-3834.
35. Limdi, N., Wiener, H., Goldstein, J., Acton, R. and Beasley, T. Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol. Dis. 43(1):119-128.
36. Marchini, J. and Howie, B. 2010. Genotype imputation for genomewide association studies. Nat. Rev. Genet. 11(7):499-511.
37. Marchini, J., Howie, B., Myers, S., McVean, G. and Donnelly, P. 2007a. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39:906-913.
38. Marchini, J., Howie, B., Myers, S., McVean, G. and Donnelly, P. 2007b. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat. Genet. 39:906-913.
39. Momary, K., Shapiro, N., Viana, M., Nutescu, E., Helgason, C. and Cavallari, L. 2007. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 8(11):1535-1544.
40. Nothnagel, M., Ellinghaus, D., Schreiber, S., Krawczak, M. and Franke, A. 2009. A comprehensive evaluation of SNP genotype imputation. Hum. Genet. 125(2):163-171.
41. Pei, Y., Li, J., Zhang, L., Papasian, C. and Deng, H. 2008. Analyses and comparison of accuracy of different genotype imputation methods. PLoS One 3(10):e3551.
42. Pei, Y., Zhang, L., Li, J. and Deng, H. 2010. Analyses and comparison of imputation-based association methods. PLoS One 5(5):e10827.
43. Przeworski, M., Hudson, R. and Di Rienzo, A. 2000. Adjusting the focus on human variation. Trends Genet. 16(7):296-302.
44. Rieder, M., Reiner, A. and Rettie, A. 2007. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J. Thromb. Haemost. 5(11):2227-2234.
45. Sanna, S., Jackson, A. U., Nagaraja, R., Willer, C. J., Chen, W. M., Bonnycastle, L. L., Shen, H., Timpson, N., Lettre, G., Usala, G., et al. 2008. Common variants in the GDF5-UQCC region are associated with variation in human height. Nat. Genet. 40(2):198-203.
46. Scheet, P. and Stephens, M. 2006. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am. J. Hum. Genet. 78:629-644.
47. Schelleman, H., Chen, Z., Kealey, C., Whitehead, A., Christie, J., Price, M., Brensinger, C., Newcomb, C., Thorn, C., Samaha, F., et al. 2007. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81(5):742-747.
48. Servin, B. and Stephens, M. 2007. Imputation-based analysis of association studies: candidate regions and quantitative traits. PLoS Genetics 3.
49. Shriner, D., Adeyemo, A., Chen, G. and Rotimi, C. N. 2010. Practical considerations for imputation of untyped markers in admixed populations. Genet. Epidemiol. 34(3):258-265.
50. Spencer, C. C. A., Su, Z., Donnelly, P. and Marchini, J. 2009a. Designing genome-wide association studies: Sample size, power, imputation, and the choice of genotyping chip. PLoS Genetics 5(5):1-13.
51. Spencer, C. C. A., Su, Z., Donnelly, P. and Marchini, J. 2009b. Designing genome-wide association studies: Sample size, power, imputation, and the choice of genotyping chip. PLoS Genetics 5(5):1-13.
52. Takahashi, H., Wilkinson, G., Nutescu, E., Morita, T., Ritchie, M., Scordo, M., Pengo, V., Barban, M., Padrini, R., Ieiri, I., et al. 2006. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16(2):101-110.
53. Team R Development Core. 2009. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria.
54. The International HapMap Consortium. 2003. The international HapMap project. Nature 426:789-796.
55. The Wellcome Trust Case-Control Consortium. 2007. Genomewide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661-678.
56. Wadelius, M., Chen, L., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R. and Deloukas, P. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1):23-34.
57. Wadelius, M., Chen, L., Lindh, J., Eriksson, N., Ghori, M., Bumpstead, S., Holm, L., McGinnis, R., Rane, A. and Deloukas, P. 2009. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4):784-792.
58. Zeggini, E., Scott, L., Saxena, R., Voight, B. and Marchini, J. 2008. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet. 40:638-645.
59. Zhang, K., Qin, Z., Chen, T., Liu, J.S., Waterman, M.S. and Sun, F. 2005. HapBlock: haplotype block partitioning and tag SNP selection software using a set of dynamic programming algorithms. Bioinformatics 21(1):131-134.
60. Zhao, H., Pfeiffer, R. and Gail, M. H. 2003. Haplotype analysis in population genetics and association studies. Pharmacogenomics 4(2):171-178.
61. Zhao, Z., Timofeev, N., Hartley, S. W., Chui, D. H., Fucharoen, S., Perls, T. T., Steinberg, M. H., Baldwin, C. T. and Sebastiani, P. 2008. Imputation of missing genotypes: an empirical evaluation of IMPUTE. BMC Genet. 9:85.
62. Zhu, Y., Shennan, M., Reynolds, K., Johnson, N., Herrnberger, M., Valdes, R. J. and Linder, M. 2007. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin. Chem. 53(7):1199-1205.